Nasdaq · CIK 0001680367
STTK Shattuck Labs, Inc.
Insider trading from SEC Form 4. Last filing Jun 15, 2026. Close $5.97 on Oct 9, 2026, +237% from the 52-week low and -26% from the high.
Shattuck Labs, Inc. (STTK) has 39 SEC Form 4 filings on file from 14 insiders, the latest filed on Jun 15, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
4 open-market trades have been scored at STTK. The newest: Mona Ashiya (director) bought $5.5M of stock on Aug 25, 2025, filed Sep 2, 2025, scored 64 (notable). 2 insiders bought within 14 days of each other around Aug 25, 2025.
STTK closed at $5.97 on Oct 9, 2026, 237% above its 52-week low and 26% below its 52-week high.
1 Form 144 notice of planned sales is on file, the latest filed Dec 4, 2024.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Shattuck Labs, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 64Notable | Mona Ashiya director buy | $5.5M 6,306,127 shares | - | +36% from low-74% from high | |
| 64Notable | Orbimed Advisors LLC director buy | $5.5M 6,306,127 shares | - | +36% from low-74% from high | |
| 26Weak | Redmile Group, LLC director, owner buy | $167k 133,371 shares | +2% | - | |
| 26Weak | Redmile Group, LLC director, owner sell | $167k 133,371 shares | -2% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 4, 2024 | Redmile Group, LLC Director, 10% Stockholder | 133,371 0.28% of outstanding | $151k | Dec 4, 2024 | none |
Transactions
The newest 50 of 67 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | Mona Ashiya director | POpen-market purchase Pre-Funded Warrants (right to buy)derivativeindirect: See Footnote | +1,041,667 | - | - | 26,519,541 | Jun 15, 2026 |
| Jun 11, 2026 | Mona Ashiya director | POpen-market purchase Pre-Funded Warrants (right to buy)derivativeindirect: See Footnote | +208,333 | - | - | 5,303,908 | Jun 15, 2026 |
| Jun 8, 2026 | Mona Ashiya director | CConversion Pre-Funded Warrants (right to buy)derivativeindirect: See Footnote | +15,366,490 | - | - | 25,477,874 | Jun 9, 2026 |
| Jun 8, 2026 | Mona Ashiya director | CConversion Pre-Funded Warrants (right to buy)derivativeindirect: See Footnote | +3,073,298 | - | - | 5,095,575 | Jun 9, 2026 |
| Jun 8, 2026 | Mona Ashiya director | CConversion Common Warrants (right to buy)derivativeindirect: See Footnote | -15,366,490 | - | - | 0 | Jun 9, 2026 |
| Jun 8, 2026 | Mona Ashiya director | CConversion Common Warrants (right to buy)derivativeindirect: See Footnote | -3,073,298 | - | - | 0 | Jun 9, 2026 |
| May 29, 2026 | Daniel G. Baker director | AGrant or award Stock Option (Right to Buy)derivative | +81,000 | $0.00 | $0 | 81,000 | Jun 2, 2026 |
| May 29, 2026 | Neil W Gibson director | AGrant or award Stock Option (Right to Buy)derivative | +81,000 | $0.00 | $0 | 81,000 | Jun 2, 2026 |
| May 29, 2026 | Helen M Boudreau director | AGrant or award Stock Option (Right to Buy)derivative | +81,000 | $0.00 | $0 | 81,000 | Jun 2, 2026 |
| May 29, 2026 | George Golumbeski director | AGrant or award Stock Option (Right to Buy)derivative | +81,000 | $0.00 | $0 | 81,000 | Jun 2, 2026 |
| May 29, 2026 | Mona Ashiya director | AGrant or award Stock Option (Right to Buy)derivative | +81,000 | $0.00 | $0 | 81,000 | Jun 2, 2026 |
| Jan 25, 2026 | Casi DeYoung Chief Business Officer | FTax withholding Common Stock | -2,286 | $4.15 | $9,487 | 73,480 | Jan 27, 2026 |
| Jan 25, 2026 | Andrew R Neill Chief Financial Officer | FTax withholding Common Stock | -2,589 | $4.15 | $11k | 228,224 | Jan 27, 2026 |
| Jan 25, 2026 | Arundathy N. Pandite Chief Medical Officer | FTax withholding Common Stock | -3,195 | $4.15 | $13k | 196,219 | Jan 27, 2026 |
| Jan 25, 2026 | Stephen Stout See Remarks | FTax withholding Common Stock | -593 | $4.15 | $2,461 | 81,529 | Jan 27, 2026 |
| Jan 10, 2026 | Casi DeYoung Chief Business Officer | FTax withholding Common Stock | -5,699 | $4.75 | $27k | 75,766 | Jan 13, 2026 |
| Jan 10, 2026 | Arundathy N. Pandite Chief Medical Officer | FTax withholding Common Stock | -6,851 | $4.75 | $33k | 199,414 | Jan 13, 2026 |
| Jan 10, 2026 | Andrew R Neill Chief Financial Officer | FTax withholding Common Stock | -6,660 | $4.75 | $32k | 230,813 | Jan 13, 2026 |
| Jan 10, 2026 | Taylor Schreiber Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +1,548,300 | $0.00 | $0 | 1,548,300 | Jan 13, 2026 |
| Jan 10, 2026 | Abhinav A. Shukla Chief Technical Officer | AGrant or award Common Stockderivative | +315,500 | $0.00 | $0 | 315,500 | Jan 13, 2026 |
| Jan 10, 2026 | Stephen Stout See Remarks | FTax withholding Common Stock | -4,153 | $4.75 | $20k | 82,122 | Jan 13, 2026 |
| Jan 10, 2026 | Casi DeYoung Chief Business Officer | AGrant or award Common Stockderivative | +381,600 | $0.00 | $0 | 381,600 | Jan 13, 2026 |
| Jan 10, 2026 | Andrew R Neill Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +549,800 | $0.00 | $0 | 549,800 | Jan 13, 2026 |
| Jan 10, 2026 | Arundathy N. Pandite Chief Medical Officer | AGrant or award Common Stockderivative | +487,800 | $0.00 | $0 | 487,800 | Jan 13, 2026 |
| Jan 10, 2026 | Stephen Stout See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +351,400 | $0.00 | $0 | 351,400 | Jan 13, 2026 |
| Aug 25, 2025 | Orbimed Advisors LLC director | POpen-market purchase Common Stockindirect: See Footnote | +5,255,106 | $0.87 | $4.6M | 5,255,106 | Sep 2, 2025 |
| Aug 28, 2025 | Mona Ashiya director | AGrant or award Stock Option (Right to Buy)derivative | +66,300 | $0.00 | $0 | 66,300 | Sep 2, 2025 |
| Aug 28, 2025 | Daniel G. Baker director | AGrant or award Stock Option (Right to Buy)derivative | +66,300 | $0.00 | $0 | 66,300 | Sep 2, 2025 |
| Aug 25, 2025 | Mona Ashiya director | POpen-market purchase Common Stockindirect: See Footnote | +5,255,106 | $0.87 | $4.6M | 5,255,106 | Sep 2, 2025 |
| Aug 25, 2025 | Orbimed Advisors LLC director | POpen-market purchase Common Stockindirect: See Footnote | +1,051,021 | $0.87 | $912k | 1,051,021 | Sep 2, 2025 |
| Aug 25, 2025 | Mona Ashiya director | POpen-market purchase Common Stockindirect: See Footnote | +1,051,021 | $0.87 | $912k | 1,051,021 | Sep 2, 2025 |
| Aug 25, 2025 | Orbimed Advisors LLC director | POpen-market purchase Pre-Funded Warrants (right to buy)derivativeindirect: See Footnote | +10,111,384 | - | - | 10,111,384 | Sep 2, 2025 |
| Aug 25, 2025 | Mona Ashiya director | POpen-market purchase Pre-Funded Warrants (right to buy)derivativeindirect: See Footnote | +10,111,384 | - | - | 10,111,384 | Sep 2, 2025 |
| Aug 25, 2025 | Orbimed Advisors LLC director | POpen-market purchase Pre-Funded Warrants (right to buy)derivativeindirect: See Footnote | +2,022,277 | - | - | 2,022,277 | Sep 2, 2025 |
| Aug 25, 2025 | Mona Ashiya director | POpen-market purchase Pre-Funded Warrants (right to buy)derivativeindirect: See Footnote | +2,022,277 | - | - | 2,022,277 | Sep 2, 2025 |
| Aug 25, 2025 | Mona Ashiya director | POpen-market purchase Common Warrants (right to buy)derivativeindirect: See Footnote | +15,366,490 | - | - | 15,366,490 | Sep 2, 2025 |
| Aug 25, 2025 | Orbimed Advisors LLC director | POpen-market purchase Common Warrants (right to buy)derivativeindirect: See Footnote | +15,366,490 | - | - | 15,366,490 | Sep 2, 2025 |
| Aug 25, 2025 | Mona Ashiya director | POpen-market purchase Common Warrants (right to buy)derivativeindirect: See Footnote | +3,073,298 | - | - | 3,073,298 | Sep 2, 2025 |
| Aug 25, 2025 | Orbimed Advisors LLC director | POpen-market purchase Common Warrants (right to buy)derivativeindirect: See Footnote | +3,073,298 | - | - | 3,073,298 | Sep 2, 2025 |
| Aug 25, 2025 | Andrew R Neill Chief Financial Officer | AGrant or award Common Stock | +64,027 | $0.87 | $56k | 237,473 | Aug 27, 2025 |
| Aug 25, 2025 | Clay B Siegall director | AGrant or award Common Stock | +128,054 | $0.87 | $111k | 128,054 | Aug 27, 2025 |
| Aug 25, 2025 | Taylor Schreiber Chief Executive Officer | AGrant or award Common Stock | +25,610 | $0.87 | $22k | 96,612 | Aug 27, 2025 |
| Aug 25, 2025 | Abhinav A. Shukla Chief Technical Officer | AGrant or award Common Stock | +5,122 | $0.87 | $4,444 | 81,258 | Aug 27, 2025 |
| Aug 25, 2025 | Stephen Stout See Remarks | AGrant or award Common Stock | +12,805 | $0.87 | $11k | 86,275 | Aug 27, 2025 |
| Aug 25, 2025 | Andrew R Neill Chief Financial Officer | AGrant or award Warrants (Right to Buy)derivative | +64,027 | - | - | 64,027 | Aug 27, 2025 |
| Aug 25, 2025 | Clay B Siegall director | AGrant or award Warrants (Right to Buy)derivative | +128,054 | - | - | 128,054 | Aug 27, 2025 |
| Aug 25, 2025 | Stephen Stout See Remarks | AGrant or award Warrants (Right to Buy)derivative | +12,805 | - | - | 12,805 | Aug 27, 2025 |
| Aug 25, 2025 | Abhinav A. Shukla Chief Technical Officer | AGrant or award Warrants (Right to Buy)derivative | +5,122 | - | - | 5,122 | Aug 27, 2025 |
| Aug 25, 2025 | Taylor Schreiber Chief Executive Officer | AGrant or award Warrants (Right to Buy)derivative | +25,610 | - | - | 25,610 | Aug 27, 2025 |
| Aug 25, 2025 | Redmile Group, LLC director, owner | AGrant or award Pre-Funded Warrants to Purchase Common Stockderivativeindirect: See Footnotes | +4,097,730 | - | - | 7,198,553 | Aug 26, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Mona Ashiyadirector
- Daniel G. Bakerofficer, director
- Helen M Boudreaudirector
- Casi DeYoungChief Business Officer
- Neil W Gibsondirector
- George Golumbeskidirector
- Andrew R NeillChief Financial Officer
- Orbimed Advisors LLCdirector, owner
- Arundathy N. PanditeChief Medical Officer
- Redmile Group, LLCowner, director
- Clay B Siegallceo, president, officer, director
- Taylor SchreiberChief Executive Officer
- Abhinav A. ShuklaChief Technical Officer
- Stephen StoutSee Remarks
Questions about STTK
Answered from the filings on this page, as of the latest one.
Are insiders buying STTK?
No. In the last 90 days no insider at Shattuck Labs, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade STTK on the open market?
Mona Ashiya (director) bought $5.5M of STTK on Aug 25, 2025 and filed the Form 4 on Sep 2, 2025. InsiderTell scored 64 (notable), with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at Shattuck Labs, Inc.?
14 people have filed a Form 4 at Shattuck Labs, Inc., among them Mona Ashiya (director), Daniel G. Baker (officer and director), Helen M Boudreau (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.